Erythrocyte-incorporated 6-mercaptopurine metabolite levels are not affected by recent drug administration during maintenance therapy for childhood acute lymphoblastic leukemia by Lauryna Aukstikalne, Ignas Klejus, Maria Thastrup, Tadas Zvirblis, Kjeld Schmiegelow, Goda Elizabeta Vaitkeviciene, Linea Natalie Toksvang

Subjects: Get full text

Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0–45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol by Linea Natalie Toksvang, Bodil Als-Nielsen, Christopher Bacon, Ruta Bertasiute, Ximo Duarte, Gabriele Escherich, Elín Anna Helgadottir, Inga Rinvoll Johannsdottir, Ólafur G. Jónsson, Piotr Kozlowski, Cecilia Langenskjöld, Kristi Lepik, Riitta Niinimäki, Ulrik Malthe Overgaard, Mari Punab, Riikka Räty, Heidi Segers, Inge van der Sluis, Owen Patrick Smith, Marion Strullu, Goda Vaitkevičienė, Hilde Skuterud Wik, Mats Heyman, Kjeld Schmiegelow

Subjects: Get full text

Pharmacokinetic–pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia by Anna Gebhard, Patrick Lilienthal, Markus Metzler, Manfred Rauh, Sebastian Sager, Kjeld Schmiegelow, Linea Natalie Toksvang, Jakob Zierk

“…Abstract In the treatment of childhood acute lymphoblastic leukemia (ALL), current protocols combine initial high-dose multiagent chemotherapy with prolonged oral therapy with 6-mercaptopurine (6MP) and low-dose methotrexate (MTX) maintenance therapy. …”
Get full text